A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
News|Articles|October 1, 2026
A recap of top FDA & regulatory news from September 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
Advertisement
Advertisement
September brought a strong slate of FDA and regulatory developments across women’s health, from a supply update on a widely used menopause therapy to a priority review designation for a non-hormonal VMS treatment. Below, the Contemporary OB/GYN team recaps the top FDA-related stories from the month.
Related to this article
A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.
ACOG issued its most comprehensive menopause guidance, grading treatments for VMS, sleep, and mood symptoms.
Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
Advertisement
Advertisement